American Society of Hirudotherapy

Ministry of Health and Medical Services — Republic of Kiribati

Kiribati MHMS · Kiribati · oceania

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Kiribati's MHMS — leech-specific authorisation pathway not independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
oceania
Country
Kiribati
Leech status
unregulated
Last ASH review
2026-05-28

Relevant Regulation Codes

  • Kiribati Pharmacy and Poisons Ordinance and amendments
  • Pacific Island Countries (PIC) joint procurement arrangements through the Pacific Pharmaceutical Procurement Service where applicable

Prescriber Requirements

  • Kiribati Medical Practitioners Board–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Kiribati MHMS registration as applicable; English and Gilbertese-language labelling per local convention. Standard cold-chain conditions, with logistical constraints typical of Micronesian atoll distribution.

Import/Export Rules

Kiribati MHMS and Ministry of Environment, Lands and Agricultural Development clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Kiribati's public health system coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific authorisation pathway not independently verified by ASH; falls under general medical-device / traditional-medicine framework as appropriate.

Related Jurisdictions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.